MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)

NCT04841811 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Almonertinib

Sponsor

Guangdong Association of Clinical Trials

Collaborators

[object Object]